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Summary Creatine deficiency syndromes, either due
to AGAT, GAMT or SLC6A8 deficiencies, lead to a
complete absence, or a very strong decrease, of
creatine within the brain, as measured by magnetic
resonance spectroscopy. While the mammalian central
nervous system (CNS) expresses AGAT, GAMT and
SLC6A8, the lack of SLC6A8 in astrocytes around the
blood–brain barrier limits the brain capacity to import
creatine from the periphery, and suggests that the CNS
has to rely mainly on endogenous creatine synthesis
through AGAT and GAMT expression. This seems
contradictory with SLC6A8 deficiency, which, despite
AGAT and GAMT expression, also leads to creatine
deficiency in the CNS. We present novel data showing
that in cortical grey matter, AGAT and GAMT are
expressed in a dissociated way: e.g. only a few cells
co-express both genes. This suggests that to allow
synthesis of creatine within the CNS, at least for a
significant part of it, guanidinoacetate must be trans-
ported from AGAT- to GAMT-expressing cells,
possibly through SLC6A8. This would explain the
creatine deficiency observed in SLC6A8-deficient
patients. By bringing together creatine deficiency syn-
dromes, AGAT, GAMT and SLC6A8 distribution in
CNS, as well as a synthetic view on creatine and
guanidinoacetate levels in the brain, this review presents
a comprehensive framework, including new hypotheses,
on brain creatine metabolism and transport, both in
normal conditions and in case of creatine deficiency.
Abbreviations
AGAT L-arginine:glycine amidinotransferase
BBB blood–brain barrier
CAT cationic amino acid transporter (system y+)
CK creatine kinase
CNS central nervous system
Cr creatine
CSF cerebrospinal fluid
GAA guanidinoacetate
GAMT guanidinoacetate methyltransferase
MCEC microcapillary endothelial cell
MRS magnetic resonance spectroscopy
SLC6A8 creatine transporter
tCr total creatine (creatine + phosphocreatine)
Introduction
In mammals, creatine (Cr) is taken up from the diet, or
can be synthesized endogenously by a two-step mech-
anism involving (i) L-arginine:glycine amidinotransfer-
ase (AGAT), which, from arginine and glycine as
substrates, yields the intermediate guanidinoacetate
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(GAA), and (ii) guanidinoacetate methyltransferase
(GAMT), which converts GAA to creatine. Creatine is
distributed through the blood and is taken up by cells
with high energy demands through a specific creatine
transporter, SLC6A8, also abbreviated as CT1, CRT1,
CRTR, CTR or CreaT (for a review, see Wyss and
Kaddurah-Daouk 2000). With the discovery of crea-
tine deficiency syndromes due to deficiency in AGAT,
GAMT or SLC6A8 (Item et al 2001; Salomons et al
2001; Sto¨ckler et al 1994; for a review, see Sto¨ckler
et al 2007), the last 15 years have seen a boost in the
creatine research field, particularly in the central
nervous system (CNS). In this review, we aim at
bringing together what is known on creatine deficiency
syndromes with the latest research on AGAT, GAMT
and SLC6A8 distribution within the brain, in order to
delineate a comprehensive framework on creatine
metabolism and transport in CNS, both in normal
conditions and in case of creatine deficiency. New
hypotheses will also be presented.
Functions of creatine within the brain
The creatine/phosphocreatine/creatine kinase (CK)
system is essential for the buffering and transport of
high-energy phosphates. In the CNS, creatine has been
shown to be essential in growth cone migration as well
as dendritic and axonal elongation, in Na+/K+-ATPase
activity, neurotransmitter release, maintenance of mem-
brane potential, Ca2+ homeostasis and the restoration
of ion gradients (Wallimann et al 1992; Wyss and
Kaddurah-Daouk 2000). Creatine was also recently
hypothesized to act as a central neuromodulator, and
particularly as co-transmitter on GABA postsynaptic
receptors (Almeida et al 2006). Finally, creatine has
been proposed to regulate appetite and weight by acting
on specific hypothalamic nuclei (Galbraith et al 2006).
Creatine deficiency syndromes
The CNS is the main organ affected in patients
suffering from creatine deficiency syndromes caused
by deficiency of AGAT, GAMT or SLC6A8 (Item
et al 2001; Salomons et al 2001; Sto¨ckler et al 1994).
These patients present neurological symptoms in
infancy (Battini et al 2002; DeGrauw et al 2002;
Schulze et al 1997). In particular, mental retardation
and delays in speech acquisition can be observed
(AGAT, GAMT and SLC6A8 deficiencies), as well
as epilepsy (GAMT and SLC6A8 deficiencies), autism,
automutilating behaviour, extrapyramidal syndrome
and hypotonia (GAMT deficiency) (for a review, see
Sto¨ckler et al 2007).
AGAT, GAMT and SLC6A8 present a wide
pattern of expression in the mammalian brain, which
has been demonstrated in rat (AGAT, GAMT and
SLC6A8), mouse (GAMT and SLC6A8) and human
(GAMT) (see below; and Braissant et al 2001a, 2005;
Galbraith et al 2006; Schmidt et al 2004; Tachikawa
et al 2004). This may, at least in part, contribute to the
diverse phenotypic spectrum of neurological symptoms
observed in AGAT-, GAMT- and SLC6A8-deficient
patients (Anselm et al 2006; Battini et al 2006;
Mercimek-Mahmutoglu et al 2006; Schulze 2003).
The recently proposed roles of creatine as co-trans-
mitter on GABA postsynaptic receptors (Almeida
et al 2006) and as regulator of appetite and weight on
specific hypothalamic nuclei (Galbraith et al 2006)
might also contribute to this phenotypic diversity.
Specific features of GAMT deficiency are probably
due to the epileptogenic effect of the accumulated
GAA (Schulze et al 2001), the activation of GABAA
receptors by GAA (Neu et al 2002) and its inhibitory
effect on Na+/K+-ATPase and CK (Zugno et al 2006).
All three deficiencies are characterized by an
absence, or a severe decrease, of creatine in the CNS,
as measured by magnetic resonance spectroscopy
(MRS) (Stromberger et al 2003; Sykut-Cegielska et al
2004). AGAT- and GAMT-deficient patients can be
treated with oral creatine supplementation. Although
very high doses of creatine are being used, the
replenishment of cerebral creatine takes months and
results only in the partial restoration of the cerebral
creatine pool (Battini et al 2002; Ganesan et al 1997;
Item et al 2001; Schulze et al 1998; Sto¨ckler et al
1996b). The pre-symptomatic treatment of AGAT-
and GAMT-deficient patients has been reported, and
appears to ameliorate the outcome for these patients
(Battini et al 2006; Schulze et al 2006; Schulze and
Battini 2007). For GAMT deficiency, lowering GAA
by arginine-restricted diet with low-dose ornithine sup-
plementation (Schulze et al 2001) or solely by high-
dose supplementation of ornithine (Schulze et al 2005)
has been shown effective. Creatine supplementation of
SLC6A8-deficient patients is inefficient in restoring
cerebral creatine levels (Bizzi et al 2002; Cecil et al
2001; DeGrauw et al 2002; Po´o-Argu¨elles et al 2006).
Expression of AGAT, GAMT and SLC6A8
within the CNS
It has long been thought that most, if not all, of the
creatine necessary for the brain is of peripheral origin,
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be it taken from the diet or synthesized endogenously
through AGAT and GAMT activities in kidney,
pancreas and liver (Wyss and Kaddurah-Daouk
2000). It has long been known, however, that the
mammalian brain is able to synthesize creatine (Pisano
et al 1963; Van Pilsum et al 1972), which is also true of
primary cultures of brain cells and nerve cell lines
(Braissant et al 2002, 2008; Cagnon and Braissant 2007;
Daly 1985; Dringen et al 1998). It has now been clearly
established that both AGAT and GAMT are
expressed within the brain, both during development
and in adulthood (Braissant et al 2001b, 2005, 2007;
Lee et al 1998; Nakashima et al 2005; Schmidt et al
2004; Tachikawa et al 2004, 2007). AGAT is expressed
throughout the adult rat CNS, including the retina, and
can be found in all the main types of brain cells,
namely neurons, astrocytes and oligodendrocytes
(Braissant et al 2001b; Nakashima et al 2005). In the
structures regulating exchanges between periphery and
CNS, as well as between brain parenchyma and
cerebrospinal fluid (CSF), AGAT is expressed in
microcapillary endothelial cells (MCEC) and the
astrocytes contacting them at the blood–brain barrier
(BBB), as well as in the choroid plexus and ependymal
epithelia (Braissant et al 2001b). GAMT is also
expressed throughout the main structures of the adult
mammalian brain, as shown in rat, mouse and human;
furthermore, GAMT is expressed by neurons, astro-
cytes and oligodendrocytes, with higher levels found in
both glial cell types (Braissant et al 2001b; Nakashima
et al 2005; Schmidt et al 2004; Tachikawa et al 2004).
GAMT is not expressed in MCEC but is present in the
astrocytes contacting them (at the BBB), as well as in
the choroid plexus and ependymal epithelia (Braissant
et al 2001b; Tachikawa et al 2004).
Organotypic rat cortical cultures, primary brain cell
cultures—neuronal, glial or mixed—and neuroblasto-
ma cell cultures have creatine uptake activity
(Almeida et al 2006; Braissant et al 2002, 2008; Daly
1985; Mo¨ller and Hamprecht 1989). In vivo, mouse and
rat CNS are able to take up creatine from the blood
against its concentration gradient, but this uptake of
creatine through the BBB seems relatively inefficient
(Ohtsuki et al 2002; Perasso et al 2003). SLC6A8 is
expressed throughout the adult mammalian brain
(Braissant et al 2001b; Galbraith et al 2006; Guimbal
and Kilimann 1993; Happe and Murrin 1995; Saltarelli
et al 1996; Schloss et al 1994). In rat and mouse,
SLC6A8 is found in neurons and oligodendrocytes,
but, in contrast to AGAT and GAMT, cannot be
detected in astrocytes (Braissant et al 2001b; Ohtsuki
et al 2002; Tachikawa et al 2004). This holds true also
for the retina, where SLC6A8 is expressed in retinal
neurons but not in astrocytes (Acosta et al 2005;
Nakashima et al 2004). In contrast to the absence of
SLC6A8 in astrocytes lining microcapillaries, MCEC
which form the BBB and the blood–retina barrier do
express SLC6A8 (Acosta et al 2005; Braissant et al
2001b; Nakashima et al 2004; Ohtsuki et al 2002;
Tachikawa et al 2004) and are able to take up creatine
(Ohtsuki et al 2002). SLC6A8 is also expressed by the
choroid plexus and the ependymal epithelia (Braissant
et al 2001b).
Creatine and guanidinoacetate within the normal
versus creatine-deficient CNS
In normal conditions, creatine within human CSF is
maintained in the 17–90 2mol/L range (Table 1 and
references therein). By MRS, total creatine (tCr) is
measured between 5.5 mmol/L and 6.4 mmol/L in the
cortical grey matter, and between 4.8 mmol/L and 5.1
mmol/L in the cortical white matter (Table 1). GAA is
maintained in human CSF at a 1000-fold lower level
than creatine, with a 0.015–0.114 2mol/L range, while
its levels in grey and white matter were estimated as
1.6 mmol/L and 0.9 mmol/L respectively (Table 1).
With the exception of SLC6A8-deficient heterozy-
gous females, where brain creatine deficiency appears
partial (Cecil et al 2003), all three creatine deficiencies
present the virtual absence (or a very strong decrease)
of the creatine peak measured by MRS in the cortical
grey and white matter or in basal ganglia (Sto¨ckler
et al 2007). However, despite the lack of detection or
decrease under MRS measure, creatine remains pres-
ent within the brain of creatine-deficient patients
(Table 1).
In SLC6A8 deficiency, creatine levels in CSF do not
seem different from those in age-matched controls
(Cecil et al 2001; DeGrauw et al 2002; Salomons et al
2001) (Table 1). In AGAT deficiency, tCr levels in
cortical grey and white matter are decreased to 12%
and 10% respectively of age-matched controls (Battini
et al 2002) (Table 1), which suggests that tCr levels in
these regions are in the 500 2mol/L range. In GAMT
deficiency, CSF levels of creatine are strongly decreased
(<2 2mol/L) compared with controls (Ensenauer et al
2004; Schulze et al 1997, 2003), while in cortical grey
and white matter, tCr levels were found to be in the
0.2–1.5 mmol/L and 0.3–1.9 mmol/L ranges, respectively
(Mancini et al 2005; Sto¨ckler et al 1994) (Table 1).
GAA accumulation in body fluids is characteristic
of GAMT deficiency, and the CSF of GAMT-deficient
patients presents levels of GAA 60–1000-fold higher
than those in age-matched controls (Table 1), while
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they are estimated to be 3.6 mmol/L and 3.4 mmol/L
within cortical grey and white matter, respectively. No
precise data are available on GAA levels within the
AGAT- and SLC6A8-deficient CNS, but it was shown
recently by MRS that GAA can also accumulate in the
brain of SLC6A8-deficient patients (Sijens et al 2005)
(see also below).
In the rodent brain, creatine concentrations were 8.5
mmol/L (rats) and 8.2 mmol/L (mice) (Renema et al
2003), or 10–11 2mol/g of tissue (mice) (Schmidt et al
2004; Torremans et al 2005) (Table 2). In mice, GAA
is maintained at a 1000-fold lower level than creatine
within CNS (0.012 2mol/g of tissue). As expected,
GAMTj/j knockout (KO) mice show decreased levels
of creatine within their brain, which however still
reach 1.4 mmol/L or 0.4–0.5 2mol/g of tissue, and a
very significant increase in GAA (1.9 2mol/g tissue;
Table 2). As for GAMT-deficient patients, GAMTj/j
KO mice slowly replenish their brain creatine upon
creatine treatment (Kan et al 2007).
Synthesis or uptake of creatine by the brain?
The in vivo expression of AGAT and GAMT within
the mammalian brain and the in vitro endogenous
synthesis of creatine by various types of cultured brain
cells suggest that the CNS synthesizes creatine (for a
review, see Braissant et al 2007). However, it was
thought for a long time that most, if not all, of the
Table 1 Creatine and guanidinoacetate in the human brain of controls and SLC6A8, AGAT or GAMT deficient patients
Cr-CSF
(2mol/L)
tCr GMa
(mmol/L) VOI
tCr WMa
(mmol/L) VOI
GAA CSF
(2mol/L)
GAA GMa
(mmol/L) VOI
GAA WMa
(mmol/L) VOI
References
Controls
ND 5.5 T 0.8 5.1 T 0.9 ND 1.6 T 1.0 0.9 T 0.9 Sto¨ckler et al (1994)
ND 6.3 T 0.7 5.1 T 0.5 ND ND ND Sto¨ckler et al (1996a)
25–70 ND ND ND ND ND Schulze et al (1997)
ND ND ND 0.114 T 0.068 ND ND Struys et al (1998)
ND 6.4T0.3 4.8 T 0.6 ND ND ND Dechent et al (1999)
ND ND ND 0.062 T 0.028 ND ND Leuzzi et al (2000)
35–90 ND ND 0.015–0.100 ND ND Schulze et al (2001)
24–66 ND ND 0.036–0.224 ND ND DeGrauw et al (2002)
24–53 ND ND ND ND ND Salomons et al (2003)
17–87 ND ND 0.020–0.560 ND ND Almeida et al (2004)
ND 6.2 T 0.5 4.9 T 0.4 ND ND ND Mancini et al (2005)
ND ND ND 0.068–0.114 ND ND Caldeira Araujo et al (2005)
SLC6A8 deficiency
62b ND ND ND ND ND Cecil et al (2001)
56 ND ND ND ND ND DeGrauw et al (2002)
ND 37%c,d ND ND ND ND Cecil et al (2003)
AGAT deficiency
ND 12%c 10%c ND ND ND Battini et al (2002)
GAMT deficiency
ND 0.2 0.3 ND 3.6 3.4 Sto¨ckler et al (1994)
<2.0 ND ND ND ND ND Schulze et al (1997)
ND ND ND 13.7 ND ND Struys et al (1998)
ND ND ND 11.0 ND ND Leuzzi et al (2000)
1.4 ND ND 6.6 ND ND Schulze et al (2003)
1.8 ND ND 15.3 ND ND Ensenauer et al (2004)
ND ND ND 14.0,15.0 ND ND Almeida et al (2004)
ND 1.4, 1.5 1.9, 1.6 ND ND ND Mancini et al (2005)
ND ND ND 11.0–12.4 ND ND Caldeira Araujo et al (2005)
a Cortical grey matter (GM) and white (WM) matter.
bWhile on Cr treatment.
c% as compared to age-matched controls.
d Basal ganglia, heterozygous female.
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creatine needed by the brain comes from the periphery
through the BBB (for a review, see Wyss and
Kaddurah-Daouk 2000).
The discovery that SLC6A8 cannot be detected in
astrocytes, particularly in their feet sheathing micro-
capillaries at the BBB suggested, however, that in the
mature brain the BBB has a limited permeability for
creatine, despite the expression of SLC6A8 by MCEC
and their capacity to import creatine (Acosta et al
2005; Braissant et al 2001b; Nakashima et al 2004;
Ohtsuki et al 2002; Tachikawa et al 2004). This is
further confirmed in vivo, both in rodents and humans.
The blood-to-brain transport of creatine through the
BBB has been demonstrated in rats and mice, but is
relatively inefficient (Ohtsuki et al 2002; Perasso et al
2003). Moreover, the long-term treatment of AGAT-
and GAMT-deficient patients with high doses of
creatine allows the replenishment of their brain
creatine pools, but is very slow and only partial
(Stromberger et al 2003; Sykut-Cegielska et al 2004).
Similarly, GAMTj/j KO mice treated with high doses
of creatine replenish their brain creatine, but only
slowly (Kan et al 2007). One possibility for the limited
entry of creatine into the brain parenchyma, without
going through astrocytes, could be the use of the
limited surface of CNS capillary endothelium that is
free of astrocytic endings (Ohtsuki 2004; Virgintino
et al 1997). This would explain that the AGAT- or
GAMT-deficient CNS, despite its very significant
decrease in creatine, still presents measurable levels
of creatine (Tables 1 and 2).
SLC6A8-deficient patients have normal levels of
creatine in CSF (Table 1) but are unable to import
creatine from the blood (Bizzi et al 2002; Cecil et al
2001; DeGrauw et al 2002; Po´o-Argu¨elles et al 2006).
In contrast, GAMT-deficient patients have strongly
decreased levels of creatine in CSF (Table 1) but are
able to import creatine from the blood (Schulze et al
1997; Sto¨ckler et al 1994). These observations are in
favour of endogenous synthesis of creatine within
CNS, which would still be operational, at least in some
brain cells, under SLC6A8 deficiency while being
completely blocked in AGAT and GAMT deficiencies
(see Fig. 1).
Thus, under normal physiological conditions, the
adult mammalian brain might depend more on its own
creatine synthesis, through the expression of AGAT
and GAMT, than on creatine supply from the blood
(Braissant et al 2001b, 2007). The brain capacity for
creatine synthesis would thus depend on the efficient
supply of arginine, the limiting substrate for creatine
synthesis, from blood to CNS, and then also on the
local trafficking of arginine between brain cells. We
and others have shown that the cationic amino acid
transporters (CATs) might fulfil these roles in the
adult rat brain, as CAT1 is expressed at the BBB as
well as ubiquitously in neuronal and glial cells, as
CAT2(B) is present in neurons and oligodendrocytes,
and as CAT3 is restricted to neurons (Braissant et al
1999, 2001a; Hosokawa et al 1999).
However, the hypothesis of endogenous creatine
synthesis in the brain might seem contradictory with
the in vivo characteristics of SLC6A8 deficiency,
which, despite expression of AGAT and GAMT
within CNS, shows an absence or a very low level of
brain creatine by MRS, as in AGAT and GAMT
deficiencies (Salomons et al 2003). This apparent
contradiction might be explained by the AGAT,
GAMT and SLC6A8 expression patterns in CNS:
AGAT and GAMT can be found in every cell type
of the brain (Braissant et al 2001b), while they rarely
seem to be co-expressed within the same cell.
Dissociated expression of AGAT, GAMT
and SLC6A8 within the brain
To elucidate this, we hypothesized that, within the
different cell types of the brain, AGAT, GAMT and
SLC6A8 might be expressed in a dissociated way, and
that GAA, which is known to compete for creatine
uptake through SLC6A8 (Ohtsuki et al 2002; Saltarelli
et al 1996), has to be transported from AGAT- to
GAMT-expressing cells, possibly through SLC6A8, for
Table 2 Creatine and guanidinoacetate in the rodent brain, including in GAMTj/j KO mice
tCr brain (mmol/L) VOI Cr brain (2mol/g tissue) GAA brain (2mol/g tissue) References
Control rats 8.5 Renema et al (2003)
Control mice 8.2 T 1.2 Renema et al (2003)
10.2 T 1.1 0.012 T 0.002 Schmidt et al (2004)
11.3 T 0.4 0.012 T 0.001 Torremans et al (2005)
GAMTj/j KO mice 1.4 T 0.4 Renema et al (2003)
0.43 T 0.09 1.87 T 0.07 Schmidt et al (2004)
0.47 T 0.09 1.85 T 0.06 Torremans et al (2005)
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creatine to be synthesized within the CNS (Braissant
et al 2007). This could explain the absence of creatine
synthesis in the brain of SLC6A8-deficient patients.
Our aim was thus first to dissect the cell-to-cell
(co-)expression of AGAT, GAMT and SLC6A8
within the adult rat brain.
To achieve this, in situ hybridization coupled to
immunohistochemistry was applied to cryosections of
rat brain (Braissant 2004), where the expression
pattern of AGAT, GAMT and SLC6A8 was analysed
within the grey matter of cortex. Specific RNA probes
and polyclonal antibodies were used (Braissant et al
2001b, 2005) to unravel, on adjacent sections, the three
different F2 by 2_ combinations of the three genes
(AGAT+GAMT; AGAT+SLC6A8; GAMT+SLC6A8).
For each combination, in situ hybridization for gene 1
was coupled to immunohistochemistry for gene 2,
followed on adjacent sections by in situ hybridization
for gene 2 coupled to immunohistochemistry for gene 1.
All combinations were repeated twice, allowing a total
of four F2 by 2_ labellings of each combination of the
three genes. With each combination, the proportions of
cells were obtained with (i) no expression of either
genes 1 or 2, (ii) expression of gene 1 only, (iii)
expression of gene 2 only, or (iv) co-expression of
genes 1 and 2, which finally allowed the calculation of
the expression pattern of AGAT, GAMT and SLC6A8
taken F3 by 3_ (Table 3).
MCEC
1
3
Cr
Cr
GAA
Arg+Gly
GAA
Arg+Gly
GAA
4 CrCr
?
AGAT
?
SLC6A8
GAMT
A:  normal
2
SLC6A8 ??
BBB
Astr.
Astr.
Astr.
Neur.
Olig.
   Neur.
Astr.,Olig.
Neur.,Olig.
Neur.
Astr.
Olig.
Neur.
Astr.
Olig.
B:  SLC6A8 deficiency
MCEC
1
3
Cr
GAA
Arg+Gly
Arg+Gly
GAA
4Cr
?
AGAT GAMT
2
BBB
?
SLC6A8
SLC6A8 ?
Astr.
Astr.
Astr.
Neur.
Olig.
   Neur.
Astr.,Olig.
Neur.,Olig.
Neur.
Astr.
Olig.
Neur.
Astr.
Olig.
AGAT
GAMT
AGAT
GAMT
Cr
GAA ?
Cr
C:  AGAT deficiency
MCEC
1
3
Cr
Arg+Gly
GAMT
Arg+Gly
4
?
?
GAMT
2
?
BBB
Cr
Cr
AGAT
AGAT
SLC6A8
SLC6A8 ? Astr.
Astr.
Astr.
Neur.
Olig.
   Neur.
Astr.,Olig.
Neur.,Olig.
Neur.
Astr.
Olig.
Neur.
Astr.
Olig.
GAA
D:  GAMT deficiency
MCEC
1
3
Cr
Arg+Gly
AGAT
GAMT
Arg+Gly
4
?
AGAT GAMT
2
BBB
GAA
Cr
Cr
GAA
SLC6A8
GAA
SLC6A8 ?
?
?
Astr.
Astr.
Astr.
Neur.
Olig.
   Neur.
Astr.,Olig.
Neur.,Olig.
Neur.
Astr.
Olig.
Neur.
Astr.
Olig.
Fig. 1 A proposed model for creatine synthesis and transport within the central nervous system. (A) normal conditions. A high
proportion of cells do not express AGAT, GAMT and SLC6A8 (1). Endogenous synthesis of creatine within CNS can be achieved
between AGAT- and GAMT-expressing cells and the concomitant trafficking of GAA between them (2), or in cells co-expressing
AGAT+GAMT (3). A low proportion of brain cells express only SLC6A8 (4; i.e. creatine users only). (B) Creatine transporter
(SLC6A8) deficiency. (C) L-arginine:glycine amidinotransferase (AGAT) deficiency. (D) Guanidinoacetate methyltransferase (GAMT)
deficiency. Other abbreviations: Arg, arginine; Astr., astrocytes; BBB, blood–brain barrier; Cr, creatine; GAA, guanidinoacetate; Gly,
glycine; MCEC, microcapillary endothelial cells; Neur., neurons; Olig., oligodendrocytes
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These experiments revealed that within grey matter
of the rat cortex, significant proportions of cells do no
express either AGAT, GAMT or SLC6A8 (30.9%), or
express AGAT only (14.8%), GAMT only (13.4%) or
SLC6A8 only (13.9%). Cortical cells co-expressing
AGAT+GAMT but not SLC6A8 were 7.9%, those
expressing AGAT+SLC6A8 but not GAMT were
6.7%, and those expressing GAMT+SLC6A8 but not
AGAT were 7.9%. Finally, cells co-expressing
AGAT+GAMT+SLC6A8 were 4.1%.
Altogether, we show that in the rat cortex, a low
proportion of cells (12%) appear capable of their own
creatine synthesis (i.e. co-expressing AGAT+GAMT),
in agreement with the creatine deficiency observed by
MRS in SLC6A8-deficient patients. Cells co-expressing
GAMT+SLC6A8, and thus equipped for creatine syn-
thesis if GAA is taken up by SLC6A8, were also 12%.
Future work will aim at deciphering whether the
proportions in the cortical expression pattern of
AGAT, GAMT and SLC6A8 are respected within
the other regions of the brain, or whether differential
expression patterns for AGAT, GAMT and SLC6A8
occur between these structures.
Models and hypotheses to understand creatine
synthesis and transport within the brain
Taking together, (i) the expression pattern of AGAT,
GAMT and SLC6A8 within CNS, (ii) the absence (or
strong decrease) of creatine within CNS of creatine-
deficient patients, (iii) the low permeability of the
BBB for creatine, and (iv) the creatine and GAA
concentrations within the brain, both in normal and in
creatine-deficient conditions, leads us to propose the
following model to understand creatine synthesis and
trafficking within CNS (Fig. 1).
In normal conditions (Fig. 1A), SLC6A8 is
expressed by CEMC, but not by the feet of surround-
ing astrocytes, implying that very limited amounts of
creatine can enter the brain through the BBB, possibly
through the limited surface of CNS capillary endothe-
lium that is free of astrocytic endings (Ohtsuki 2004;
Virgintino et al 1997). Within the cortical grey matter,
the high proportion of cells without expression of
AGAT, GAMT and SLC6A8 and the low proportion
of cells expressing only SLC6A8 suggest that brain
cells express AGAT, GAMT and SLC6A8 on demand
to adapt their creatine needs in timely manner. Cells
equipped with the full creatine synthesis pathway (i.e.
co-expressing AGAT and GAMT) are only 12%.
Finally, the dissociated expression of AGAT and
GAMT among different cells suggests that to allow
synthesis of creatine within CNS, at least for a
significant part of it, GAA must be transported from
AGAT- to GAMT-expressing cells, possibly through
SLC6A8 as 12% of cortical cells co-express SLC6A8
and GAMT.
Creatine supplementation of SLC6A8-deficient
patients (Fig. 1B) does not restore creatine levels in
their brain, as MCEC of these patients lack functional
SLC6A8. Moreover, if SLC6A8 also allows GAA
uptake, SLC6A8-deficient patients should lack the
creatine synthesis pathway from AGAT-expressing to
GAMT+SLC6A8 co-expressing cells. This would ex-
plain why SLC6A8-deficient patients lack (or present a
significant decrease in) creatine in CNS as measured
by MRS, having only a small proportion of their brain
cells equipped to self-synthesize creatine.
In AGAT deficiency (Fig. 1C), no creatine can be
synthesized within the brain, but the expression of
SLC6A8 in MCEC allows the very limited entry of
creatine within the CNS. Because of the SLC6A8
expression in MCEC, the brain of AGAT-deficient
(Co)-expression pattern
for AGAT, GAMT
and SLC6A8
Percentage of cells
within gray matter
(cortex)
1 – (no expression) 30.9 T 6.5
2 AGAT alone 14.8 T 2.3
3 GAMT alone 13.4 T 3.6
4 SLC6A8 alone 13.9 T 4.1
5 AGAT+GAMT 7.9 T 2.1
6 AGAT+SLC6A8 6.7 T 1.4
7 GAMT+SLC6A8 7.9 T 3.3
8 AGAT+GAMT+SLC6A8 4.1 T 1.6
No AGAT, no GAMT, no SLC6A8 (1) 30.9 T 6.5
Total AGAT+GAMT (5+8) 12.0 T 3.7
Total GAMT+SLC6A8 (7+8) 12.0 T 4.9
Table 3 Dissociated expression
of AGAT, GAMT and SLC6A8
in the telencephalic cortex of
the rat (grey matter). The
proportions (%) of cells with
the respective (co-)expression
patterns for AGAT, GAMT
and SLC6A8 are indicated.
Mean T SD (n = 4)
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patients can be replenished in creatine by oral creatine
treatment.
Finally in GAMT deficiency (Fig. 1D), no creatine
can be synthesized within the brain, and GAA accu-
mulates. As for AGAT deficiency, the expression of
SLC6A8 in MCEC allows the very limited entry of
creatine within CNS, as well as the replenishment of the
GAMT-deficient CNS through oral creatine treatment.
To clarify these models and hypotheses, important
questions remain to be solved. Future research in the
field of brain creatine should aim at analysing the
capacity of brain cells to take up GAA and, if this is
shown, to demonstrate whether this uptake occurs
through SLC6A8. Another important point is to
identify how creatine (and GAA) can leave the cells,
and whether SLC6A8 or another mechanism is in-
volved. Finally, does the brain of SLC6A8-deficient
patients accumulate GAA as suggested in our model?
So far, data are poor on the GAA level in the brain of
SLC6A8-deficient patients. However, a recent work
does indeed demonstrate that GAA does not accumu-
late in the CNS only in the case of GAMT deficiency,
but can also be augmented in the brain of SLC6A8-
deficient patients (Sijens et al 2005). The fact that
SLC6A8-deficient patients can also develop epilepsy
(Hahn et al 2002; Mancardi et al 2007; Po´o-Argu¨elles
et al 2006) is also suggestive of GAA accumulation in
the SLC6A8-deficient CNS.
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